European Journal of Clinical Pharmacology

, Volume 64, Issue 9, pp 877–882

CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

Pharmacogenetics

Abstract

Purpose

Our aim was to observe the impact of CYP3A4*1G genetic polymorphism on lipid-lowering efficacy of statins.

Methods

We studied 217 unrelated hyperlipidemic patients who prospectively received atorvastatin and 199 patients who received simvastatin as a single-agent therapy (20 mg day-1 p.o.) for 4 weeks. Genotyping of CYP3A4*1G was conducted by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were determined before and after treatment by enzymatic assays.

Results

The frequency of CYP3A4*1G in Chinese hyperlipidemic patients was 0.276. After atorvastatin treatment, the mean percentage reduction in serum TC was 16.8 ± 3.3% (*1/*1), 17.8 ± 3.8% (*1/*1G), and 20.9 ± 5.0% (*1G/*1G), respectively. The CYP3A4*1G polymorphism had a gene-dose-dependent effect on percentage reduction in serum TC (P < 0.01). Conversely, there was no significant association between lipid-lowering efficacy of simvastatin and CYP3A4*1G polymorphism.

Conclusions

Carrying CYP3A4*1G increase the lipid-lowering efficacy of atorvastatin and may have no significant effect on simvastatin treatment.

Keywords

CYP3A4 Polymorphisms Simvastatin Atorvastatin Lipid-lowering efficacy 

References

  1. 1.
    Vaughan CJ, Gotto AM, Basson CT (2000) The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35:1–10PubMedCrossRefGoogle Scholar
  2. 2.
    Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschini G, Sirtori CR (1995) Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Atherosclerosis 117:189–198PubMedCrossRefGoogle Scholar
  3. 3.
    Shimada T, Yamazaki H, Mimura M et al (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423PubMedGoogle Scholar
  4. 4.
    Paine MF, Khalighi M, Fisher JM et al (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552–1562PubMedGoogle Scholar
  5. 5.
    de Waziers I, Cugnenc PH, Yang CS et al (1990) Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387–394PubMedGoogle Scholar
  6. 6.
    Wrighton SA, VandenBranden M, Ring BJ (1996) The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 24:461–473PubMedCrossRefGoogle Scholar
  7. 7.
    Ozdemir V, Kalowa W, Tang BK et al (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373–388PubMedCrossRefGoogle Scholar
  8. 8.
    Lee SJ, Goldstein JA (2005) Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6:357–371PubMedCrossRefGoogle Scholar
  9. 9.
    Wang A, Yu BN, Luo CH et al (2005) Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 60:843–848PubMedCrossRefGoogle Scholar
  10. 10.
    Kajinami K, Brousseau ME, Ordovas JM et al (2004) CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 93:104–107PubMedCrossRefGoogle Scholar
  11. 11.
    Fiegenbaum M, da Silveira FR, Van der Sand CR et al (2005) The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 78:551–558PubMedCrossRefGoogle Scholar
  12. 12.
    Fukushima-Uesaka H, Saito Y, Watanabe H et al (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotype in a Japanese population. Human Mutation 26:100–108CrossRefGoogle Scholar
  13. 13.
    Du J, Yu L, Wang L et al (2007) Differences in CYP3A4*1G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations. Clin Chim Acta 383:172–174PubMedCrossRefGoogle Scholar
  14. 14.
    Hu YF, Tu JH, Tan ZR et al (2007) Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 37:315–327PubMedCrossRefGoogle Scholar
  15. 15.
    Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117–125PubMedCrossRefGoogle Scholar
  16. 16.
    Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, pp 16–19Google Scholar
  17. 17.
    Thummel KE, Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 39:1–17Google Scholar
  18. 18.
    Guengerich FP (1999) Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 38:389–430Google Scholar
  19. 19.
    Prueksaritanont T, Gorham LM, Ma B et al (1997) In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25:1191–1199PubMedGoogle Scholar
  20. 20.
    Vickers S, Duncan CA, Chen I-W et al (1990) Metabolic disposition studies of simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 18:138–145PubMedGoogle Scholar
  21. 21.
    Prueksaritanont T, Ma B, Yu N (2003) The human hepatic metabolism of simvastatin hydroxyl acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 56:120–124PubMedCrossRefGoogle Scholar
  22. 22.
    Black AE, Hayes RN, Roth BD et al (1999) Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 27:916–923PubMedGoogle Scholar
  23. 23.
    Malhotra HS, Goa KL (2001) Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 61:1835–1881PubMedCrossRefGoogle Scholar
  24. 24.
    Kantola T, Krivisto KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharamacol Ther 64:58–65CrossRefGoogle Scholar
  25. 25.
    Siedlik PH, Olson SC, Yang BB (1999) Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 39:501–504PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of PharmacologySchool of Medicine, Zhengzhou UniversityZhengzhouChina

Personalised recommendations